Literature DB >> 28103961

A review of altered biochemistry in the anterior cingulate cortex of first-episode psychosis.

L Squarcina1, J A Stanley2, M Bellani3, C A Altamura4, P Brambilla4.   

Abstract

Relevant biochemicals of the brain can be quantified in vivo, non-invasively, using proton Magnetic Resonance Spectroscopy (¹H MRS). This includes metabolites associated with neural general functioning, energetics, membrane phospholipid metabolism and neurotransmission. Moreover, there is substantial evidence of implication of the frontal and prefrontal areas in the pathogenesis of psychotic disorders such as schizophrenia. In particular, the anterior cingulate cortex (ACC) plays an important role in cognitive control of emotional and non-emotional processes. Thus the study of its extent of biochemistry dysfunction in the early stages of psychosis is of particular interest in gaining a greater understanding of its aetiology. In this review, we selected ¹H MRS studies focused on the ACC of first-episode psychosis (FEP). Four studies reported increased glutamatergic levels in FEP, while other four showed preserved concentrations. Moreover, findings on FEP do not fully mirror those in chronic patients. Due to conflicting findings, larger longitudinal ¹H MRS studies are expected to further explore glutamatergic neurotransmission in ACC of FEP in order to have a better understanding of the glutamatergic mechanisms underlying psychosis, possibly using ultra high field MR scanners.

Entities:  

Keywords:  Magnetic resonance spectroscopy; anterior cingulate cortex; brain biochemistry; first episode psychosis

Mesh:

Year:  2017        PMID: 28103961      PMCID: PMC6998769          DOI: 10.1017/S2045796016000895

Source DB:  PubMed          Journal:  Epidemiol Psychiatr Sci        ISSN: 2045-7960            Impact factor:   6.892


  25 in total

1.  Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers.

Authors:  Jean Théberge; Robert Bartha; Dick J Drost; Ravi S Menon; Ashok Malla; Jatinder Takhar; Richard W Neufeld; John Rogers; William Pavlosky; Betsy Schaefer; Maria Densmore; Yousef Al-Semaan; Peter C Williamson
Journal:  Am J Psychiatry       Date:  2002-11       Impact factor: 18.112

Review 2.  Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis.

Authors:  Nina Vanessa Kraguljac; Meredith Reid; David White; Rebecca Jones; Jan den Hollander; Deborah Lowman; Adrienne Carol Lahti
Journal:  Psychiatry Res       Date:  2012-09-13       Impact factor: 3.222

Review 3.  Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies.

Authors:  Anouk Marsman; Martijn P van den Heuvel; Dennis W J Klomp; René S Kahn; Peter R Luijten; Hilleke E Hulshoff Pol
Journal:  Schizophr Bull       Date:  2011-07-11       Impact factor: 9.306

4.  Multivoxel proton MR spectroscopy used to distinguish anterior cingulate metabolic abnormalities in patients with schizophrenia.

Authors:  Caitlin J Hardy; Assaf Tal; James S Babb; Nissa N Perry; Julie W Messinger; Daniel Antonius; Dolores Malaspina; Oded Gonen
Journal:  Radiology       Date:  2011-09-07       Impact factor: 11.105

5.  Glutamatergic metabolite correlations with neuropsychological tests in first episode schizophrenia.

Authors:  Kara Dempster; Ross Norman; Jean Théberge; Maria Densmore; Betsy Schaefer; Peter Williamson
Journal:  Psychiatry Res       Date:  2015-06-19       Impact factor: 3.222

6.  3-T proton magnetic spectroscopy in unmedicated first episode psychosis: a focus on creatine.

Authors:  Philip G Tibbo; Denise Bernier; Christopher C Hanstock; Peter Seres; Bonnie Lakusta; Scot E Purdon
Journal:  Magn Reson Med       Date:  2012-04-17       Impact factor: 4.668

7.  1 H-MR spectroscopy in ultra-high risk and first episode stages of schizophrenia.

Authors:  Idun Uhl; Paraskevi Mavrogiorgou; Christine Norra; Frank Forstreuter; Michael Scheel; Henning Witthaus; Seza Ozgürdal; Yehonala Gudlowski; Georg Bohner; Jürgen Gallinat; Randolf Klingebiel; Andreas Heinz; Georg Juckel
Journal:  J Psychiatr Res       Date:  2011-03-11       Impact factor: 4.791

Review 8.  Cingulate Cortex in Schizophrenia: its relation with negative symptoms and psychotic onset. A review study.

Authors:  F S Bersani; A Minichino; M Fojanesi; M Gallo; G Maglio; G Valeriani; M Biondi; P B Fitzgerald
Journal:  Eur Rev Med Pharmacol Sci       Date:  2014-11       Impact factor: 3.507

9.  Reduced N-acetyl-aspartate levels in schizophrenia patients with a younger onset age: a single-voxel 1H spectroscopy study.

Authors:  Jeffrey A Stanley; Madhuri Vemulapalli; Jeffrey Nutche; Debra M Montrose; John A Sweeney; Jay W Pettegrew; Frank P MacMaster; Matcheri S Keshavan
Journal:  Schizophr Res       Date:  2007-05-10       Impact factor: 4.939

Review 10.  Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis.

Authors:  Kate Merritt; Philip McGuire; Alice Egerton
Journal:  Front Psychiatry       Date:  2013-11-26       Impact factor: 4.157

View more
  3 in total

1.  Anterior Cingulate Glutamate and GABA Associations on Functional Connectivity in Schizophrenia.

Authors:  Dinesh K Shukla; S Andrea Wijtenburg; Hongji Chen; Joshua J Chiappelli; Peter Kochunov; L Elliot Hong; Laura M Rowland
Journal:  Schizophr Bull       Date:  2019-04-25       Impact factor: 7.348

Review 2.  Changes in the anterior cingulate cortex in Crohn's disease: A neuroimaging perspective.

Authors:  Ning Kong; Chen Gao; Maosheng Xu; Xuning Gao
Journal:  Brain Behav       Date:  2020-12-12       Impact factor: 2.708

3.  Neurophysiological Effects of the Anterior Cingulate Cortex on the Exacerbation of Crohn's Disease: A Combined fMRI-MRS Study.

Authors:  Ning Kong; Chen Gao; Fan Zhang; Meng Zhang; Juan Yue; Kun Lv; Qi Zhang; Yihong Fan; Bin Lv; Yufeng Zang; Maosheng Xu
Journal:  Front Neurosci       Date:  2022-05-06       Impact factor: 4.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.